FilingReader Intelligence
Lukang Pharmaceutical wins drug approval after 12.8m yuan investment
August 14, 2025 at 05:00 AM UTC•By FilingReader AI
Shandong Lukang Pharmaceutical received approval from the National Medical Products Administration for its cefuroxime axetil dry suspension, confirming successful passage of consistency evaluation for generic drugs.
The company invested approximately 12.82 million yuan in research and development for this product's consistency evaluation. Domestic sales of cefuroxime axetil reached approximately 1.087 billion yuan in 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shandong Lukang Pharmaceutical publishes news
Free account required • Unsubscribe anytime